科美诊断技术股份有限公司2025年年度业绩预告

Group 1 - The company forecasts a net profit attributable to shareholders of the parent company for 2025 to be between RMB 40 million and RMB 48 million, representing a year-on-year decrease of 62.23% to 68.52% compared to the previous year [2] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between RMB 26 million and RMB 32 million, reflecting a year-on-year decline of 68.23% to 74.19% [2] - The previous year's net profit attributable to shareholders of the parent company was RMB 127.07 million, with a net profit after deducting non-recurring gains and losses of RMB 100.73 million [4] Group 2 - The decline in net profit is primarily due to the impact of centralized procurement in the in vitro diagnostics industry, which has pressured product prices and led to a decrease in main business revenue [6] - The company has maintained high R&D investment to enhance core competitiveness, which has contributed to the profit decline [7] - There has been a reduction in government subsidies and other non-recurring gains compared to the previous year [8]